As reported by Manas Mishra,” Zogenix announced a drug to treat childhood epilepsy reduced convulsive seizures in a second late-stage trial.” The company reports that it took a step closer to commercialize the drug. It is following the approval of GW Pharmaceutical’s Pic’s cannabis-based treatment for the same form of epilepsy.
Mishra noted “In the trial, the treatment reduced the frequency of convulsive seizures by 62.7 percent on median, compared with a 1.2 percent reduction in patients taking placebo, meeting the main goal of the trial.” Zogenix plans on submitting marketing approval applications to authorities such as the FDA and EMA. The target for these applications is Fourth quarter 2018.
Zogenix said it would now focus on submitting applications for marketing approval of its drug in the United States and Europe in the fourth quarter of 2018.
Investigator sites working on the trial are listed here
Based in Emeryville, California, Zogenix has about 70 employees. As of TSN writing it has a reported market capitalization of $1.97 billion on a $55.90 stock price. 52 week high/low is $58.30 and $10.05. The latest financials were not available but the company operates at a loss. Top equity holders include Perceptive Advisors LLC, Scopia Capital Management LP, Blackrock Inc, and FMR LLC.
View article hereSource: Nasdaq